News An aura of adult migraine hope as NICE recommends Vyepti Lundbeck’s eptinezumab receives NICE recommendation for the prevention of migraine in adults.
News Amid crowded migraine market, Lundbeck goes its own way The market for migraine treatment and prevention has been transformed by the launch of several new drugs targeting CGRP for many sufferers, but Lundbeck thinks there is still room for new a
News FDA approves 'potential blockbuster' migraine jab from Lundb... The FDA has approved Lundbeck’s eptinezumab prophylactic treatment for migraine, the last from a gang of four drugs from a new class.
Market Access The changing landscape of drug clinical assessment: Tommy Br... In a new pharmaphorum podcast, Tommy Bramley, SVP of market access and healthcare consulting at Cencora, discusses Joint Clinical Assessments.
Market Access The value of a partner, globally and locally A new podcast looks at recent trends related to drug approvals, as well as challenges and opportunities both small and large pharma companies face
